ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

BHST vs SXTC // EV/EBITDA & P/E VALUATION

BioHarvest Sciences Inc. (NASDAQ) VS. China SXT Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: BHST 6 — SXTC 0
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BHST VS. SXTC) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC BHST SXTC SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 59.30% 21.90% +37.40 BHST /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% — — TIE /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin -16.20% -60.00% +43.80 BHST /operating-margins <GO>
Net Profit Margin -32.30% -60.00% +27.70 BHST /net-margins <GO>
Revenue Growth (YoY) 37.00% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 5/9 1/9 +4.00 BHST /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 48.0 27.7 +20.26 BHST /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $37.6M $367.7K $37.3M BHST /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR BHST REV SXTC REV BHST GROSS % SXTC GROSS % BHST FCF SXTC FCF
FY 2025 $34.5M $1.1M 59.3% 21.9% -$9.6M -$4.0M
FY 2024 $25.2M $1.7M 55.4% 21.1% -$9.5M -$2.3M
FY 2023 $12.7M $1.9M — — -$8.5M -$1.9M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BHST // BETA —
SXTC // BETA —